FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to molecules of diabodies and to their use for treating various diseases and disorders, including immunological disorders, infectious disease, intoxication and malignant tumors. According to the invention, the diabodies molecules contain two polypeptide chains which are associated with the formation of at least two epitope binding sites, which can recognize one or different epitopes on one or different antigens.
EFFECT: invention can be used for effective treatment of autoimmune disorder.
29 cl, 49 dwg, 17 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| TRISPECIFIC BINDING MOLECULES FOR TREATING VIRAL HEPATITIS B INFECTION AND BOUND STATES | 2016 |
|
RU2733496C2 |
| ANTIBODIES BINDING TO GPRC5D | 2020 |
|
RU2841523C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
